Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

Next Previous
Search
Trial Profile

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PRT 3645 (Primary)
  • Indications Advanced breast cancer; Astrocytoma; Endometrial cancer; Glioblastoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Malignant-mesothelioma; Mouth neoplasm; Non-small cell lung cancer; Oropharyngeal cancer; Sarcoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Prelude Therapeutics

    • Most Recent Events

    • 01 Jul 2024 Status changed from active, no longer recruiting to completed.
    • 15 Jan 2024 Status changed from recruiting to active, no longer recruiting.
    • 14 Oct 2023 According to a Prelude Therapeutics media release, initial data presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, known as the Triple Meeting, from October 11-15, 2023 at the Hynes Convesntion Center in Boston, MA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top